Title:
胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
Document Type and Number:
Japanese Patent JP7036791
Kind Code:
B2
Abstract:
The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and methods of the invention can be used to dose subjects with oxytocin antagonists, including (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, among others, so as to improve endometrial receptivity and reduce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) embryo transfer procedures.
Inventors:
Roumaye, Ernest
Gotland, Jean-Pierre
Gotland, Jean-Pierre
Application Number:
JP2019502231A
Publication Date:
March 15, 2022
Filing Date:
July 20, 2017
Export Citation:
Assignee:
Obseva S.A.
International Classes:
A61K31/40; A61K9/20; A61K31/57; A61K35/54; A61K38/24; A61P5/06; A61P5/34; A61P15/08; G01N33/50; G01N33/68
Domestic Patent References:
| JP2008540519A |
Foreign References:
| WO2015036160A1 | ||||
| WO2016105190A1 | ||||
| US20110020847 |
Attorney, Agent or Firm:
Longhua International Patent Service Corporation
Previous Patent: A device for treating GERD
Next Patent: Spiro-lactam NMDA receptor modifiers and their use
Next Patent: Spiro-lactam NMDA receptor modifiers and their use